Notwithstanding encouraging clinical results, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant resistance from pharmacy benefit managers. These organizations are frequently erecting limitations to access, like high cost requirements and prior authorization that restrict patient